In vitro models demonstrated that the re-establishment of PTEN expression restores sensitivity to gefitinib [ 21].
In this study we present the development of a tissue-engineered 3D model of the oral mucosa using a native complex dermal matrix to produce three in vitro models demonstrating histopathological malignant transformation through dysplasia, carcinoma in situ to early invasive carcinoma.
Therefore, the results of the in vitro model demonstrate that ozagrel, at least in part, protects against APAP hepatotoxicity by inhibiting the oncotic necrosis of hepatocytes.
Our in vitro model demonstrates that HIV-induced tryptophan catabolism has a direct negative effect on CD4 and CD8 T cell proliferative responses.
Positive functional data were defined as any in vivo or in vitro model, demonstrating results differing from the wild-type model.
Importantly, an in vitro model demonstrated that exposure to low levels of imatinib promoted the development of genomic amplification, whereas effective drug levels did not (Le Coutre et al, 2000).
Although in vitro model demonstrated that PDK-1 is the AKT (T308) kinase (Alessi et al, 1997; Wick et al, 2000b; Williams et al, 2000), the clinical association between these two molecules remained to be validated.
In vitro expression models demonstrate that HIV protease also has the ability to cleave several cellular targets to induce apoptosis, including Bcl-2.
Furthermore, results from in vitro culture models demonstrate that IGF-I can significantly increase embryonic development and blastocyst formation (Lighten et al., 1998; Liu et al., 1999; Fried et al., 2003).
In vitro and in vivo models demonstrated the ability of the 177Lu-DOTA-8-Aoc-BBN[7-14]NH2 conjugato to specifically target GRP receptors expressed on PC-3 human prostate cancer cells.
